Follow the people · Insider
Muna Bhanji
Muna Bhanji files insider transactions with the SEC as a director of Veracyte (VCYT). We hold 1 disclosed purchase or sale filed since 18 February 2021, 1 of them in the last 90 days.
- Files forVCYT
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure3 September 2026
Positions held
4 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 19 March 2021 — 1 September 2026Director · Veracyte (VCYT)13 Form 4 lines · source: SEC Form 4
- Filed 11 March 2021 — 16 June 2026Director · Ardelyx (ARDX)9 Form 4 lines · source: SEC Form 4
- Filed 28 April 2022 — 9 June 2026Director · Intellia Therapeutics (NTLA)17 Form 4 lines · source: SEC Form 4
- Filed 17 February 2021 — 27 May 2026Director · Cytokinetics (CYTK)20 Form 4 lines · source: SEC Form 4
Everything they disclosed
59 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 1,864 shares of VeracyteSEC Form 43 September 2026Common Stock · traded 1 September 2026 · filed 3 September 2026
- was granted 26,455 shares of ArdelyxSEC Form 418 June 2026Common Stock · traded 16 June 2026 · filed 18 June 2026
- was granted 39,715 shares of Ardelyx (a derivative holding)SEC Form 418 June 2026Stock Option (Right to Buy) · traded 16 June 2026 · filed 18 June 2026
- was granted 5,272 shares of VeracyteSEC Form 415 June 2026Common Stock · traded 11 June 2026 · filed 15 June 2026
- was granted 9,200 shares of Intellia TherapeuticsSEC Form 410 June 2026Common Stock · traded 9 June 2026 · filed 10 June 2026
- was granted 13,300 shares of Intellia Therapeutics (a derivative holding)SEC Form 410 June 2026Stock Option (right to buy) · traded 9 June 2026 · filed 10 June 2026
- was granted 2,851 shares of CytokineticsSEC Form 427 May 2026Common Stock · traded 27 May 2026 · filed 27 May 2026
- was granted 4,301 shares of Cytokinetics (a derivative holding)SEC Form 427 May 2026Non-Qualified Stock Option (Right to Buy) · traded 27 May 2026 · filed 27 May 2026
- was granted 9,321 shares of VeracyteSEC Form 423 June 2025Common Stock · traded 18 June 2025 · filed 23 June 2025
- was granted 54,059 shares of Ardelyx (a derivative holding)SEC Form 423 June 2025Stock Option (Right to Buy) · traded 18 June 2025 · filed 23 June 2025
- was granted 41,551 shares of ArdelyxSEC Form 423 June 2025Common Stock · traded 18 June 2025 · filed 23 June 2025
- ▼ sold on the open market 4,589 shares of VeracyteSEC Form 417 June 2025Common Stock · traded 13 June 2025 · filed 17 June 2025
- was granted 11,450 shares of Intellia Therapeutics (a derivative holding)SEC Form 413 June 2025Stock Option (right to buy) · traded 11 June 2025 · filed 13 June 2025
- was granted 8,000 shares of Intellia TherapeuticsSEC Form 413 June 2025Common Stock · traded 11 June 2025 · filed 13 June 2025
- ▼ sold on the open market 1,454 shares of CytokineticsSEC Form 415 May 2025Common Stock · traded 15 May 2025 · filed 15 May 2025
- was granted 10,880 shares of Cytokinetics (a derivative holding)SEC Form 414 May 2025Non-Qualified Stock Option (Right to Buy) · traded 14 May 2025 · filed 14 May 2025
- was granted 7,333 shares of CytokineticsSEC Form 414 May 2025Common Stock · traded 14 May 2025 · filed 14 May 2025
- ▼ sold on the open market 265 shares of Intellia TherapeuticsSEC Form 41 May 2025Common Stock · traded 29 April 2025 · filed 1 May 2025
- ▼ sold on the open market 265 shares of Intellia TherapeuticsSEC Form 431 January 2025Common Stock · traded 29 January 2025 · filed 31 January 2025
- was granted 11,473 shares of VeracyteSEC Form 417 June 2024Common Stock · traded 13 June 2024 · filed 17 June 2024
- was granted 40,243 shares of Ardelyx (a derivative holding)SEC Form 417 June 2024Stock Option (Right to Buy) · traded 14 June 2024 · filed 17 June 2024
- was granted 11,515 shares of Intellia Therapeutics (a derivative holding)SEC Form 414 June 2024Stock Option (right to buy) · traded 12 June 2024 · filed 14 June 2024
- was granted 7,737 shares of Intellia TherapeuticsSEC Form 414 June 2024Common Stock · traded 12 June 2024 · filed 14 June 2024
- ▼ sold on the open market 3,870 shares of VeracyteSEC Form 411 June 2024Common Stock · traded 10 June 2024 · filed 11 June 2024
- ▼ sold on the open market 2,000 shares of CytokineticsSEC Form 410 June 2024Common Stock · traded 10 June 2024 · filed 10 June 2024
- ▼ sold on the open market 1,539 shares of VeracyteSEC Form 430 May 2024Common Stock · traded 28 May 2024 · filed 30 May 2024
- was granted 3,636 shares of Cytokinetics (a derivative holding)SEC Form 416 May 2024Non-Qualified Stock Option (Right to Buy) · traded 15 May 2024 · filed 16 May 2024
- was granted 5,600 shares of CytokineticsSEC Form 416 May 2024Common Stock · traded 15 May 2024 · filed 16 May 2024
- ▼ sold on the open market 265 shares of Intellia TherapeuticsSEC Form 42 November 2023Common Stock · traded 31 October 2023 · filed 2 November 2023
- ▼ sold on the open market 265 shares of Intellia TherapeuticsSEC Form 42 August 2023Common Stock · traded 31 July 2023 · filed 2 August 2023
- ▼ sold on the open market 1,867 shares of Intellia TherapeuticsSEC Form 410 July 2023Common Stock · traded 6 July 2023 · filed 10 July 2023
- ▼ sold on the open market 2,000 shares of CytokineticsSEC Form 47 July 2023Common Stock · traded 7 July 2023 · filed 7 July 2023
- ▼ sold on the open market 5,793 shares of VeracyteSEC Form 421 June 2023Common Stock · traded 16 June 2023 · filed 21 June 2023
- ▼ sold on the open market 100 shares of VeracyteSEC Form 421 June 2023Common Stock · traded 16 June 2023 · filed 21 June 2023
- was granted 6,473 shares of Intellia Therapeutics (a derivative holding)SEC Form 416 June 2023Stock Option (right to buy) · traded 14 June 2023 · filed 16 June 2023
- was granted 4,425 shares of Intellia TherapeuticsSEC Form 416 June 2023Common Stock · traded 14 June 2023 · filed 16 June 2023
- was granted 49,237 shares of Ardelyx (a derivative holding)SEC Form 416 June 2023Stock Option (Right to Buy) · traded 15 June 2023 · filed 16 June 2023
- was granted 9,674 shares of VeracyteSEC Form 413 June 2023Common Stock · traded 9 June 2023 · filed 13 June 2023
- ▼ sold on the open market 1,539 shares of VeracyteSEC Form 41 June 2023Common Stock · traded 30 May 2023 · filed 1 June 2023
- was granted 10,000 shares of Cytokinetics (a derivative holding)SEC Form 418 May 2023Non-Qualified Stock Option (Right to Buy) · traded 10 May 2023 · filed 18 May 2023
- was granted 5,000 shares of CytokineticsSEC Form 418 May 2023Common Stock · traded 10 May 2023 · filed 18 May 2023
- was granted 220 shares of CytokineticsSEC Form 45 October 2022Common Stock · traded 3 October 2022 · filed 5 October 2022
- was granted 274 shares of CytokineticsSEC Form 412 July 2022Common Stock · traded 1 July 2022 · filed 12 July 2022
- was granted 100,000 shares of Ardelyx (a derivative holding)SEC Form 417 June 2022Stock Option (Right to Buy) · traded 15 June 2022 · filed 17 June 2022
- was granted 95,802 shares of ArdelyxSEC Form 417 June 2022Common Stock · traded 15 June 2022 · filed 17 June 2022
- was granted 2,980 shares of Intellia Therapeutics (a derivative holding)SEC Form 416 June 2022Stock Option (right to buy) · traded 14 June 2022 · filed 16 June 2022
- was granted 2,014 shares of Intellia TherapeuticsSEC Form 416 June 2022Common Stock · traded 14 June 2022 · filed 16 June 2022
- was granted 14,731 shares of VeracyteSEC Form 416 June 2022Common Stock · traded 16 June 2022 · filed 16 June 2022
- was granted 10,000 shares of Cytokinetics (a derivative holding)SEC Form 411 May 2022Non-Qualified Stock Option (right to buy) · traded 10 May 2022 · filed 11 May 2022
- was granted 5,000 shares of CytokineticsSEC Form 411 May 2022Common Stock · traded 10 May 2022 · filed 11 May 2022
- was granted 11,700 shares of Intellia Therapeutics (a derivative holding)SEC Form 42 May 2022Stock Option (Right to Buy) · traded 28 April 2022 · filed 2 May 2022
- was granted 7,954 shares of Intellia TherapeuticsSEC Form 42 May 2022Common Stock · traded 28 April 2022 · filed 2 May 2022
- was granted 293 shares of CytokineticsSEC Form 41 April 2022Common Stock · traded 1 April 2022 · filed 1 April 2022
- was granted 244 shares of CytokineticsSEC Form 44 January 2022Common Stock · traded 3 January 2022 · filed 4 January 2022
- was granted 10,000 shares of Cytokinetics (a derivative holding)SEC Form 413 May 2021Non-Qualified Stock Option (right to buy) · traded 12 May 2021 · filed 13 May 2021
- was granted 5,000 shares of CytokineticsSEC Form 413 May 2021Common Stock · traded 12 May 2021 · filed 13 May 2021
- was granted 11,541 shares of VeracyteSEC Form 423 March 2021Common Stock · traded 19 March 2021 · filed 23 March 2021
- was granted 63,687 shares of Ardelyx (a derivative holding)SEC Form 415 March 2021Stock Option (Right to Buy) · traded 11 March 2021 · filed 15 March 2021
- was granted 35,000 shares of Cytokinetics (a derivative holding)SEC Form 418 February 2021Non-Qualified Stock Option (right to buy) · traded 17 February 2021 · filed 18 February 2021
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.